XERSXeris Biopharma Holdings Inc
XERS
Xeris Biopharma Holdings Inc10,693
Mkt Cap
$1.07BVolume
384,742.0052W High
$10.0852W Low
$4.30PE Ratio
94.50XERS Fundamentals
Price
$6.17Prev Close
$6.19Open
$6.2450D MA
$5.98Beta
1.27Avg. Volume
1.35MEPS (Annual)
$0.0032P/B
82.10Rev/Employee
$670,908.05$1,503.09
About
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
435
Frequently Asked Questions
What is Market Cap of Xeris Biopharma Holdings Inc?
What is the 52-week high for Xeris Biopharma Holdings Inc?
What is the 52-week low for Xeris Biopharma Holdings Inc?
What is Xeris Biopharma Holdings Inc stock price today?
What was Xeris Biopharma Holdings Inc stock price yesterday?
What is the PE ratio of Xeris Biopharma Holdings Inc?
What is the Price-to-Book ratio of Xeris Biopharma Holdings Inc?
What is the 50-day moving average of Xeris Biopharma Holdings Inc?
How many employees does Xeris Biopharma Holdings Inc have?
Compact View
Not available
Not available
